Articles On Proteomics International Laboratories (ASX:PIQ)

 Monash IVF has rejected an initial 80 cents a share offer from a consortium accounting for 19.6% of the company Mesoblast to launch phase III trial for adults with graft-versus-host disease Island joins germ warfare coalition of the will...

The latest quarterlies show that key drug and diagnostics developers are well funded for the task Cann Group enters company-saving debt and equity restructuring deal A rebirth for Monash IVF?      Today’s crop of quarterly reports shows t...

Highlights NexSen debuts on ASX with rapid diagnostics focus. Point-of-Care Testing market growth supports new listings. Small-cap biotech sector gains investor attention. NexSen (ASX:NXN) debuts in the ASX stock market, offering...

Proteomics International (ASX: PIQ) has achieved a significant milestone with the granting of ISO 15189 certification for its Australian laboratory operations. The medical testing certification – which adds to Proteomics’ existing ISO 17025...

 Oncosil will accelerate the rollout of its targeted radiation device after promising trial results Imricor completes ‘human factor’ ablation catheter study PYC’s CEO departure is “disappointing”, opines broker   The developer of a targe...

Ramsay says its full-year earnings met investors’ expectations – and if anything, were a tad higher Pacific Edge wins higher US reimbursement – but there’s a catch Leading up to AGMs, biotechs do the boardroom blitz   The ASX’s corporate...

Nexsen is commercialising novel point-of-care diagnostic tech developed by RMIT University The company’s first target is group B streptococcus (GBS) bacteria, a potentially dangerous disease affecting one in six pregnant women. Nexsen is...

New blood test reveals hidden muscle damage in racehorses Proteomics’ OxiDx helps trainers spot injuries early and avoid breakdowns ASX-listed stocks with exposure to the animal sector.   In the high-octane world of thoroughbred racing, m...

Imugene reports two more ‘complete responders’ in its cell therapy trial Clever Culture Systems shares surge 17% on deal with Big Pharma Novo Nordisk  Compumedics shares vault 24% after full-year update   Imugene (ASX:IMU) will forge ahea...

Highlights Bioxyne outpaces sector peers with performance in cannabis and health products Paradigm Biopharmaceuticals secures convertible note funding for late-stage trial Recce Pharmaceuticals and Botanix turn to debt as eq...

Bioxyne stars with a 720% gain in the 2024-25 year Paradigm shares soar 34% after $41 million convertible note deal Biotechs turn to debt funding The ASX biotech sector’s best EOFY performer has come from left field: the local and Europ...

Dreadnought Resources (ASX:DRE) has been the most watched on HotCopper forums through today after announcing an extension of its Mangaroon Gold Project in Western Australia. Listen to the HotCopper podcast for in-depth discussions and in...

Proteomics (ASX:PIQ) has seen shares pop just over +4% in early Friday trades after launching its PromarkerD product into the US on the back of the 85th Scientific Sessions of the American Diabetes Association (ADA). PromarkerD is a bloo...

Proteomics International (ASX:PIQ) has popped as much as +6% today after reporting the “high accuracy” of its blood test for throat cancer. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headline...

Medical device makers – including ASX-listed heart plays – are the likely winners from the US healthcare chaos Painchek hopes for US device approval by September Mayne Pharma flags legal action over Cosette bid but also waves an olive bra...

 Having produced more positive diagnostics results, Proteomics plans to launch its Promarker Endo device locally this year Immutep posts more positive trial results, this time for soft tissue sarcoma Broker values EBR Systems share price a...

ASX heath sector up 1.9%, trailing ASX 200’s 2% gain in short week revival   Sleep-related respiratory disorders company ResMed reports “stronger than expected” Q3 FY25 results Imricor makes key regulatory strides in Q1 CY25, including sub...

ASX climbs 0.3pc before falling flat to end at -0.04pc Financial and consumer staples sectors outperform to limit losses Energy plummets more than 2.5pc as oil outlook darkens   Between looming pharmaceuticals and semiconductor tariffs an...

Precision diagnostics company Proteomics International Laboratories Ltd (ASX:PIQ) has been granted a patent in Australia for its OxiDx test. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlin...

Proteomics International Laboratories (ASX: PIQ) has officially launched its unique PromarkerD predictive test for diabetic kidney disease in Australia. PromarkerD is a clinically validated blood test that helps predict the risk of developi...

 Proteomics launches its diabetic kidney disease assay in Australia Trivarx lines up a sleep-related depression study with US Veterans Affairs The vibes from Trumpland are not great for research-stage biotechs   It’s World Kidney Day, whe...

The health sector awaits the Trump Administration’s first moves under health czar RFK Junior Key Republicans love supplements and that bodes well for EZZ Life Sciences Proteomics prepares to launch four finger-prick predictive tests   The...

Highlights    ASX closes slightly down as markets experience slow trading and profit-taking.    Energy and Healthcare emerge as top-performing sectors.    Real Estate leads sectoral declines with significant losses.    The A...

The ASX closed down 0.04% on the second last trading day of 2024, losing three points to drop down to 8,221 as slow trade and profit-taking raked markets. The last full day of trading (remember, New Year’s Eve will see the Aussie bourse...

Highlights - ASX faced a modest dip amid global caution and ex-dividend activity.  - BrainChip Holdings (BRN) soared despite no clear catalyst for its rise.  - Prominent small-cap stocks showcased diverse developments and partnerships....

Mixed revenue trends emerge from the latest batch of quarterly updates Proteomics plans to launch its predictive diabetes test next year Chimeric raises $5 million – but drops its daks to do so   As the end-of-October quarterly reporting...

Tony Locantro has been a client advisor/investment manager in the stockbroking industry since 1998. He’s focused on the small cap and emerging companies with a strong interest in identifying those in the mining, biotech and industrial secto...

Health Check is renowned biotech journo Tim Boreham’s daily wrap covering morning movers and shakers of note in the ASX Healthcare sector, Monday through Thursday.   Proteomics blood-based test showed 94% accuracy in both detecting and rul...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin World Overnight SPI Overnight 8168.00 + 53.00 0.65% S&P ASX 200 8121.60 +...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin World Overnight SPI Overnight 8116.00 + 16.00 0.20% S&P ASX 200 8099.90 +...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin World Overnight SPI Overnight 8119.00 + 49.00 0.61% S&P ASX 200 8075.70 +...

  ASX falls on Wednesday with banks dragging down market Lithium stocks surge on CATL suspension reports; MinRes hits new high Energy stocks struggle as Brent drops below US$70   The ASX was on the back foot on Wednesday, down by 0.3%  w...

The ASX200 has been down 0.3% at 7,988 points in early afternoon trade. Gold prices have climbed back to record levels during the US Trump-Harris Presidential debate on Wednesday morning, just under $2,520 per ounce American. Futures...

Proteomics International Laboratories Ltd (ASX:PIQ) has seen its share price plunge more than 20% on news that it has ended its exclusive agreement with Sonic Healthcare USA relating to the use and commercialisation of PromarkerD – its pred...

Proteomics and US partner Sonic Healthcare say ‘I don’t’ and go their separate ways The company hopes to launch its PromarkerD diagnostic tool in the US in the current financial year Virtual health IT provider Visionflex VFX has unveiled t...

Proteomics International Laboratories’ “PromarkerD” device that uses a simple finger-prick blood test has shown a high accuracy in being able to predict future kidney disease in type 1 diabetes patients.

Proteomics International Laboratories (ASX: PIQ) has obtained what it describes as “groundbreaking” results in its development of treatments for deadly type 1 diabetes. More than 130,000 Australians live with type 1 diabetes, which currentl...

Proteomics International Laboratories has sealed a new deal with medical diagnostics company Eurobio Scientific to distribute its predictive “PromarkerD” test for diabetic kidney disease in France.

Proteomics International Laboratories is escalating its expansion into the European market after appointing sales agency Growth Medics to promote its “PromarkerD” predictive test for diabetic kidney disease.

Predictive diagnostics medical company Proteomics International Laboratories (ASX: PIQ), has engaged Growth Medics B.V., to assist with the identification and selection of EU alliance partners for its PromarkerD predictive test for diabetic...

Having served as Proteomics chief since he co-founded the company in 2001, Dr Richard Lipscombe is used to setbacks and delays. On March 18, Proteomics (ASX:PIQ) said it would not be able to meet the June 2024 timeline for the US launch of...

Research conducted by Proteomics International Laboratories and Curtin University has made a crucial discovery in understanding how dieback impacts plants in a potentially significant agriculture breakthrough.

Predictive diagnostics specialist Proteomics International Laboratories (ASX: PIQ) has signed an agreement with the University of Oxford to acquire approximately 600 patient plasma samples for a study into endometriosis. The samples will be...

  Markets are less volatile as traders anticipate easing of rates But the path in Australia may not be that easy, says CIO at Martin Currie Aussie CPI data to grab economics headlines this week   The ASX is set to have another crack at a...

The ASX200 has closed the trading day just above even. The sectors were split, with Financials leading gains, adding about half a per cent, while the Real Estate sector took a big hit ahead of this week’s interest rates decisions here an...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

World Overnight SPI Overnight 7729.00 + 14.00 0.18% S&P ASX 200 7712.50 + 8.30 0.11% S&P500 5175.27 + 57.33 1.12% Nasdaq Comp 16265.64 + 246.36 1.54% DJIA 39005.49 + 235.83 0.61% S&P500 VIX 13.84 – 1.38 – 9.07% U...

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.11% to 7,712.50. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spotify...

Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. It involves betting that the stock market’s recent winners will remain winners. One of the best known momentum traders in the world is hedge f...

Predictive diagnostics company Proteomics International Laboratories (ASX:PIQ) has successfully retained its ISO 13485 certification, an internationally recognised standard for safety and quality management systems in the manufactur...